A small molecule called K-7174 was found to ease neuropsychiatric symptoms of systemic lupus erythematosus (SLE) in a recent study in mice, and even helped to improve cognitive function. Researchers found that treatment with the molecule may protect against neuropsychiatric SLE (NPSLE) by preserving the selective blood-brain barrier (BBB),…
Reduced lymphatic drainage might explain why skin reactions to sunlight, or photosensitivity, may lead to systemic immune reactions and overall disease flareups in people with systemic lupus erythematosis (SLE), a study suggests. Data showed that the flow of the skin’s lymphatic fluid — which sends cells and molecular signals to…
A CAR T-cell therapy targeting disease-driving immune cells safely led to sustained disease remission for five people with systemic lupus erythematosus (SLE) who’d previously failed to respond to other treatments, a recent study reported. Treatment was also highly specific, preventing autoimmune activity, but didn’t impair general immune system…
Equillium’s investigational antibody-based treatment, itolizumab (EQ001), led to significant reductions in urine protein levels — a marker of kidney dysfunction — in systemic lupus erythematosus (SLE) patients with active lupus nephritis, according to an interim analysis from the type B portion of the Phase 1b EQUALISE clinical trial.
Antibodies mounted against COVID-19 in the three to six months following vaccination were lower in patients undergoing treatment for lupus than in healthy people, a study has found. Patients with untreated lupus (also called systemic lupus erythematosus, or SLE) showed a similar level of antibodies as healthy people. Fewer…
Litifilimab (BIIB059), Biogen’s investigational antibody-based treatment for systemic lupus erythematosus (SLE), significantly reduced the number of swollen and tender joints in people with the autoimmune inflammatory disease over six months, new trial data show. With these positive results, the treatment candidate met the main goal of part A of the…
A Phase 2 trial testing the effectiveness of afimetoran, Bristol-Myers Squibbs’ (BMS) investigational oral treatment for people with systemic lupus erythematosus (SLE), is underway. In-human testing was supported by preclinical evidence that demonstrated the therapy’s ability to prevent or reverse disease symptoms and halt death in mouse models. The…